Podcast episode
Ideas to Innovation
On June 7th, the U.S. Food and Drug Administration approved aducanumab, the first new Alzheimer’s treatment since 2003. Aducanumab is a monoclonal antibody that has been shown to reduce the buildup of a protein known as beta amyloid that some think might be a possible cause of Alzheimer’s disease. While the approval has been applauded by some, it is not without controversy. In this session, we ask our guests how innovation in the search for treatments of Alzheimer’s disease is evolving.